Kleanthis G. Xanthopoulos, President and CEO at Regulus Therapeutics Inc. (RGLS), sold 70 shares at $19.50 ($1K) on 2015-02-27, disclosed to the SEC on 2015-03-03.
Scheduled sale ($1k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| RGLS | SELL | 2015-03-05 | $1.8M | — | Filing → |
| RGLS | SELL | 2015-02-03 | $112K | — | Filing → |
| RGLS | SELL | 2015-01-30 | $2.6M | — | Filing → |